# US 2019/0315767 A1 · Tricyclic ask1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315767 A1
- Document ID: US20190315767A1
- Status: Published application
- Kind: A1
- Application number: 16/382,936
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-12
- Assignees: Terns, Inc.
- Applicants: Terns, Inc.
- Inventors: Yingzi XU; Randall HALCOMB; Thorsten A. KIRSCHBERG; F. Anthony ROMERO
- Web page: https://patentgrep.com/patent/US20190315767A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 498/10: Spiro-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.

## Claims

### Claim 1

A compound of formula (IA):
or a pharmaceutically acceptable salt thereof, wherein:
ring A is an optionally substituted 5-membered heteroaryl ring;
ring B is C6-C10 aryl or 5- to 10-membered heteroaryl;
L1 is optionally substituted C2-C6 alkylene or optionally substituted C2-C6 heteroalkylene;
L2 is —CO—NH—, —NH—CO—, —SO2—NH—, or —NH—SO2—;
R1 is optionally substituted C3-C8 cycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- to 6-membered heteroaryl, optionally substituted 4- to 6-membered heterocyclyl, —CONR11R12 or —SO2NR11R12;
R11 and R12 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
or R11 and R12 are taken together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocyclyl;
X1, X2, and X3 are independently CR2 or N;
each R2 is independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C8 cycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 4- to 10-membered heterocyclyl, halo, —NO2, haloalkyl, haloalkoxy, —CN, —O—R3, —S—R3, —N(R3)(R4), —S(═O)—R3, —S(═O)2R3, —S(═O)2—N(R3)(R4), —S(═O)2—O—R3, —N(R3)—C(O)—R4, —N(R3)—C(O)—O—R4, —N(R3)—C(O)—N(R3)(R4), —C(O)—R3, —C(O)—O—R3, —C(O)—N(R3)(R4), or —N(R3)—S(═O)2—R4; and
R3 and R4 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C8 cycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- to 10-membered heteroaryl, and optionally substituted 5- to 10-membered heterocyclyl;
or R3 and R4 are taken together with the nitrogen atom or with the intervening atoms to which they are attached to form an optionally substituted 4- to 10-membered heterocyclyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
ring B is phenyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
ring A is
and
R40 is H, C1-C6 alkyl, or halo.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
L1 is —O-L10-; and
L10 is optionally substituted C1-C5 alkylene or optionally substituted C1-C5 heteroalkylene.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
L1 is
and
R100 and R101 are independently H, optionally substituted C1-C6 alkyl, halo, optionally substituted C3-C5 cycloalkyl, optionally substituted 4- to 5-membered heterocyclyl, or optionally substituted 5-membered heteroaryl;
or R100 and R101 are taken together with the carbon atom or carbon atoms to which they are attached to form a C3-C5 cycloalkyl.

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:
R100 and R101 are independently H; C1-C6 alkyl optionally substituted with 1-3 hydroxyl or halo; halo; C3-C5 cycloalkyl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo; 4- to 5-membered heterocyclyl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo; or 5-membered heteroaryl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo;
or R100 and R101 are taken together with the carbon atom or carbon atoms to which they are attached to form a C3-C5 cycloalkyl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
L1 is —O—CH2—CH2—, —O—CH2—CH(Me)-, —O—CH2—C(Me)2-, —O—CH(Me)-CH2—, —O—CH2—CH(CH2OH)—, —O—CH2—CH(CH2F)—,

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
L2 is —CO—NH—.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is C3-C8 cycloalkyl, 6-membered aryl, 5- to 6-membered heteroaryl, or 4- to 6-membered heterocyclyl, each of which is optionally substituted with 1-2 C1-C6 alkyl or with one C3-C6 cycloalkyl which is optionally substituted with 1-2 substituents selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl; —CONR11R12; Or —SO2NR11R12.

### Claim 10 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein:
R1 is

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 is hydrogen; C1-C6 alkyl optionally substituted with 1-3 halo, —CF3, —OCF3, hydroxyl, —CN or —N(R3)(R4); C1-C6 alkoxy optionally substituted with 1-3 halo, —CF3, —OCF3, hydroxyl, —CN or —N(R3)(R4); C3-C8 cycloalkyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, —CN or —N(R3)(R4); 6-membered aryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); 5- to 10-membered heteroaryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, —CN or —N(R3)(R4); 5- to 10-membered heterocyclyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, —CN or —N(R3)(R4); or halo; and
R3 and R4 are independently selected from the group consisting of hydrogen; C1-C6 alkyl optionally substituted with 1-3 halo, —CF3, —OCF3, hydroxyl, or —CN; C3-C8 cycloalkyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN; 6-membered aryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN; 5- to 10-membered heteroaryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN; or 5- to 10-membered heterocyclyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN;
or R3 and R4 are taken together with the nitrogen atom or with the intervening atoms to which they are attached to form a 4- to 10-membered heterocyclyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN.

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X1 is N or CR2; and
R2 is halo.

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X2 is CH.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X3 is CR2; and
R2 is hydrogen; C1-C6 alkyl optionally substituted with 1-2 halo or hydroxyl; C1-C6 alkoxy optionally substituted with 1-2 halo or hydroxyl; 4-10 membered heterocyclyl optionally substituted with 1-2 C1-C6 alkyl or hydroxyl; —O—R3; or —N(R3)(R4); and
R3 and R4 are independently hydrogen or C1-C6 alkyl;
or R3 and R4 are taken together with the nitrogen atom or with the intervening atoms to which they are attached to form a 4- to 7-membered heterocyclyl optionally substituted with 1-2 C1-C6 alkyl or hydroxyl.

### Claim 15 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:
X3 is CR2; and
R2 is H, —CH3, —OCH(CH3)2, —N(CH3)2,

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is of formula (5A) or (5B):
wherein:
R100 and R101 are independently H; C1-C6 alkyl optionally substituted with 1-3 hydroxyl or halo; halo; C3-C5 cycloalkyl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo; 4- to 5-membered heterocyclyl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo; or 5-membered heteroaryl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo;
or R100 and R101 are taken together with the carbon atom or carbon atoms to which they are attached to form a C3-C5 cycloalkyl.

### Claim 17

A compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

### Claim 19 (depends on 1)

A method of inhibiting ASK1, comprising contacting ASK1 with an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

A method of treating a disorder which is mediated by ASK1, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disorder which is mediated by ASK1 is pulmonary arterial hypertension (PAH), diabetic kidney disease, heart failure, a vascular disease, a neurodegenerative disorder, an inflammatory disease, or liver disease.

### Claim 22 (depends on 21)

The method of claim 21, wherein the disorder is liver disease.

### Claim 23 (depends on 22)

The method of claim 22, wherein the liver disease is a chronic liver disease.

### Claim 24 (depends on 22)

The method of claim 22, wherein the liver disease is nonalcoholic steatohepatitis (NASH).
